Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Oculus Gets $5.1 Mln Licensing Fee From More Pharma

Oculus Innovative Sciences, Inc. (OCLS: Quote),a California-based nutrition and drug company, Thursday said it received a $5.1 million payment in view of a licensing agreement it executed on August 9, 2012, with More Pharma.

More Pharma had agreed earlier to pay an upfront $5.1 million fee for the exclusive licensing of Oculus' Microcyn-based human healthcare products in Mexico, South/Central America and the Caribbean.

Further, More Pharma will underwrite all costs for regulatory reviews and approval efforts needed for the transition of the marketing and sales effort in the aforementioned countries, said Oculus.

Wednesday, Oculus closed at $0.94 on the Nasdaq.

Click here to receive FREE breaking news email alerts for Oculus Innovative Sciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving mostly higher over the course of the previous week, stocks showed a notable move back to the downside during trading on Monday. With the drop on the day, the Dow pulled back well off last Friday's record closing high. After reporting four consecutive monthly increases, the National Association of Realtors released a report on Monday showing an unexpected drop in U.S. existing home sales in the month of August. NAR said existing home sales fell 1.8 percent to a seasonally adjusted annual rate of 5.05 million in August. The European Central Bank remains ready to use additional unconventional tools to counter risks to the inflation outlook and to boost the euro area economy, ECB President Mario Draghi said on Monday. "The Governing Council remains fully determined to counter risks to the medium-term outlook for inflation," Draghi said in Brussels.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.